Anavex Life Sciences is carving a niche in the pharmaceutical industry with its groundbreaking work on Anavex 2-73, a promising treatment for Parkinson’s disease. The company has focused its research on neurodegenerative disorders, seeking solutions that address both the cognitive and motor symptoms associated with these conditions. Anavex 2-73, also known as blarcamesine, works […]